JSR Life Sciences - About the company
JSR Life Sciences is an unfunded company based in Sunnyvale (United States), founded in 2012. It operates as a Developer of raw materials for the production of biopharmaceuticals. JSR Life Sciences has not raised any funding yet. The company has 1970 active competitors, including 448 funded and 319 that have exited. Its top competitors include companies like Antheia, Transcenta and Akeso.
Company Details
JSR Life Sciences develops raw materials for the production of biopharmaceuticals. The company's product portfolio includes Magnosphere, magnetic microparticles for life science research and in vitro diagnostic use. The beads are available in two different types of surface characteristics; hydrophilic (MS) and hydrophobic (MX); Blockmaster, a blocking agent composed of chemically synthesized polymers; IMMUTEX, a uniform-sized polystyrene latex (PSL) particle for agglutination tests in clinical diagnostics; and Amsphere A3, chromatography resin.
- Website
- www.jsrlifesciences.com
- Social
- Email ID
- *****@jsrlifesciences.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2012
Location
Sunnyvale, United States
Stage
Unfunded
Ranked
100th among 1970 active competitors
Employee Count
37 as on Aug 31, 2026
Sign up to download JSR Life Sciences' company profile
JSR Life Sciences's funding and investors
JSR Life Sciences has not raised any funding rounds yet.
JSR Life Sciences' founders and board of directors
Founder? Claim ProfileJSR Life Sciences' employee count trend
JSR Life Sciences has 37 employees as of Aug 26. Here is JSR Life Sciences's employee count trend over the years:
Uncover JSR Life Sciences' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
JSR Life Sciences's Competitors and alternates
Top competitors of JSR Life Sciences include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of JSR Life Sciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
2nd | Transcenta 2019, Suzhou (China), Public | Developer of antibody-based therapeutics | $205M | 66/100 | |
3rd | Developer of antibody drug conjugates for the treatment of broad spectrum diseases | $195M | 65/100 | ||
4th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 64/100 | |
5th | Novogene Corporation 2011, Beijing (China), Series B | Provider of genomic services and solutions | $75M | 64/100 | |
6th | Fermentalg 2005, Libourne (France), Public | Innovating with algae for sustainable solutions in nutrition and environmental impact | $30.3M | 63/100 | |
7th | Microban 1994, Huntersville (United States), Acquired | Antimicrobial and odor control technologies for durable product protection and freshness | $64.6M | 63/100 | |
8th | LifeMine Therapeutics 2016, Watertown (United States), Series E | Developer of novel drugs from fungi via genome mining and recombinant overexpression | $563M | 63/100 | |
9th | Dewpoint Therapeutics 2018, Boston (United States), Series D | Developer of small molecule based therapeutics | $364M | 62/100 | |
10th | One Biosciences 2020, Paris (France), Series A | Developer of single-cell therapeutics solutions to treat multiple health disorders | $22.4M | 62/100 | |
100th | JSR Life Sciences 2012, Sunnyvale (United States), Unfunded | Developer of raw materials for the production of biopharmaceuticals | - | - | 50/100 |
_1523881431192.png?devicePixelRatio=2&height=30&width=30){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on JSR Life Sciences's competitors? Click here to see the top ones
JSR Life Sciences's Investments and acquisitions
JSR Life Sciences has made 1 investment in AbSci and acquired Selexis and KBI Biopharma.Here is the list of these investments and acquisitions:
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Dec 18, 2019 | Investments | 2011 | Vancouver (United States) | |
Jun 14, 2017 | Acquisition | 2001 | Plan les Ouates (Switzerland) | |
Feb 26, 2015 | Acquisition | 1996 | Durham (United States) |
Want to know more about where corporates are investing? Sign up today!Reports related to JSR Life Sciences
Here is the latest report on JSR Life Sciences's sector:
News related to JSR Life Sciences
Filter this listMedia has covered JSR Life Sciences for a total of 5 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.
•
A-share Hong Kong stock Adicon Holdings (09860) subsidiary to acquire CRO company for $204 millionCnyes•Nov 13, 2025•JSR Life Sciences, Miramar Global, Crown Bioscience, Jprsystems and 1 other
•
Merck to Acquire JSR’s Chromatography Business to Strengthen Downstream Bioprocessing PortfolioBioPharma APAC•Oct 16, 2025•JSR Life Sciences, Merck, Merck
•
MilliporeSigma to Acquire Chromatography Business of JSR Life Sciences, Expanding Protein A Capabilities and Downstream PortfolioBusiness Wire•Oct 15, 2025•Sigma Aldrich, JSR Life Sciences
•
US-based Crown Bioscience expands Singapore facility with advanced oncology models and imaging capabilitiesBioSpectrum Asia•Oct 02, 2024•Crown Bioscience, JSR Life Sciences
•
Crown Bioscience’s Global Oncology Research Facilities Achieve Prestigious ISO and CAP AccreditationsKorea Newswire•Jan 24, 2024•Crown Bioscience, JSR Life Sciences
•
KBI Biopharma, Argonaut Partner on Drug Product & Mfg. ServicesContract Pharma•Jan 16, 2024•Argonautms, KBI Biopharma, JSR Life Sciences
•
JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as One Organization, Delivering a Seamless Partner ExperienceBusiness Wire•May 31, 2023•JSR Life Sciences, KBI Biopharma, Selexis
•
Similis Bio partners with Novel351k to develop multiple biosimilar programs targeting cancer and autoimmune diseasesBusiness Wire•Feb 14, 2023•JSR Life Sciences, Novel351k
•
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting BiobankBusiness Wire•Jan 25, 2023•Crown Bioscience, Indivumed, JSR Life Sciences, Freshfields Bruckhaus Deringer
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about JSR Life Sciences
Explore our recently published companies
- Folly Factory - Unfunded company
- Smash Interactive - Miami based, 2014 founded, Unfunded company
- Eat - Tinley Park based, 1989 founded, Unfunded company
- 400 Conejos - San Francisco based, 2023 founded, Unfunded company
- Tim Luedtke - Unfunded company
- Web Traffic Watch - Austria based, Unfunded company
